Philly-based Google Cloud exec Moyer settles AWS non-compete suit, Geekwire reported

Phillip Moyer / LinkedIn

Tom Paine

GeekWire reported that Amazon Web Services has settled its lawsuit against Phillip Moyer, a former Microsoft and Safeguard Scientifics exec who jumped from AWS to Google Cloud last year. Terms of the settlement were not disclosed.

Moyer, who remains Philly-based according his LinkedIn Profile, in July jumped from being AWS’ sales chief for financial services to a similar role with Google Cloud, except for healthcare and life sciences. AWS sued him for allegedly violating the non-compete clause of his contract.

Last October, a federal judge placed limitations on Moyer’s role with Google Cloud until the case was resolved.

Washington state last year passed legislation that narrowed the effective scope of non-compete clauses.

Philly EnterpriseTech Weekend Highlights

Amazon goes for Fairway stores

Tom Paine

Amazon has bid on-and is expected to prevail in acquiring- four stores from the upscale grocery Fairway Market, which declared bankruptcy in January, the New York Post reported.

Two stores are in New York (Brooklyn and Westchester County) and two are in New Jersey (Woodland Park and Paramus), according to the report.

It is uncertain how Amazon would position the stores, but it is said to be considering starting a new chain totally separate from its Whole Foods operation. Amazon is also opening a cashierless Amazon Go grocery store in Seattle.

But since grocery chains tend to be geographically contiguous, the purchase of these stores may signal future east coast expansion.

Fairway, with origins in the Upper West Side of Manhattan, operates 14 stores in New York state, Connecticut and New Jersey. Its bankruptcy is largely attributed to its heavy debt load.

Suzanne Shugg
Suzanne Shugg of TelePlus at a recent TechLaunch BullPen (file photo) | Esther Surden

NEW JERSEY STARTUP TELEPLUS OFFERS PUBLIC HEALTH APPROACH TO MITIGATING CORONAVIRUS PANDEMIC

Esther Surden

NJ TechWeekly

 March 12, 2020  Esther Surden0Around New JerseyHealth TechNewsNJ Tech CompaniesStartupsWomen in Tech,

TelePlus Healthcare, a Summit-based startup focused on managing chronic health conditions to prevent the need for hospital admissions, has launched an all-out effort to help hospitals and government agencies manage the coronavirus pandemic.

NJTechWeekly.com spoke to Suzanne Shugg, TelePlus Healthcare’s founder and CEO, on Monday, about the company’s public health approach to COVID-19.

The startup’s methodology starts with education and telemedicine, where patients can check in and describe their current symptoms, learn about risks and be told what to do. Patients can also speak to a healthcare provider for recommendations or treatments via tablets, phones or computers.

Physician Education

In addition, TelePlus has created a physician education program, to train doctors on how to manage their patients’ COVID-19 infections. Those who participate will be given access to the company’s portal, which will enable them to manage their patients remotely. Through this program, TelePlus has been expanding the number of physicians who can meet the current needs of our sick population.  

Shugg described the reasoning behind this approach. She started by referring to an NPR report, in which Richard Waldhorn, a pulmonary critical care physician who’s done research on hospital preparedness at the Johns Hopkins Center for Health Security, says that the federal government’s planning assumptions based on past flu pandemics suggest a surge in demand for intensive care that could range somewhere between 200,000 and 2.9 million patients, However, the total number of existing intensive-care-unit beds is about 65,000. So, by identifying the population at risk before they need to go to the hospital, and providing intervention, TelePlus hopes to the mitigate the demand for those beds.

To get started, the patient-centered protocol works like this: When in contact with TelePlus  health providers, patients will be asked why they think they have the virus. Do they have a fever? Do they have a cough? What are their symptoms? “We’ll find out if they’ve done any recent travel or visited any recent meetings or conferences,” Shugg said.

If the answer is yes, “We ask specific questions about arrival, such as did they get an Uber to their plane or train, because this all needs to be documented so we can track all this stuff. We’ll ask about recent contact with an infected person. Do you know who this person is? What their address is? Where they work? We’d just be trying to create a picture so that we get all that information. If a person has a fever of over 100.5 degrees, that could indicate that they are getting into trouble.”

Using Remote Monitoring

Shugg said that they’d then work on immediately outfitting patients with Bluetooth-equipped thermometers and pulse oximeters, which measure blood oxygen saturation.

One of the differences between the TelePlus approach and single-contact hospital or clinic visits is that, once the remote devices are issued, the company and its associated doctors will be able to monitor patients multiple times a day for two weeks. The patients are not left on their own, as would be the case after a one-and-done visit. Shugg said that this approach would help prevent the spread of the disease and minimize deaths.

“We have telemedicine two-week management protocols to monitor temperature, pulse ox, location and contacts — developed based on the data from Wuhan, where the pandemic first started. We ask five questions daily, and the patient takes their temperatures and pulse ox every four hours. Patients can take these measurements more often if they don’t feel well.” TelePlus has partnered with epidemiologists and infectious disease doctors who are experts in this field, Shugg said.

“We know from the data from China that when people get in trouble, their pulse ox begins to drop.”

Suzanne Shugg, TelePlus Healthcare

“We know from the data from China that when people get in trouble, their pulse ox begins to drop.” Also, their temperature rises. They develop a SARS-like syndrome, she said, which involves the lungs. If they can predict who is going to be at risk for the SARS-like syndrome, there are certain blood pressure medications — called “angiotensin-converting enzyme inhibitors” (ACE inhibitors)and “angiotensin II receptor blockers” (ARBs) — that limit the harm that SARS does to the lungs, and these drugs could be used to help these patients, Shugg said.

The company is developing algorithms to scale this approach and integrate into electronic health records. It’s ready to do so, but needs some funding, she noted.

The TelePlus COVID-19 plan includes hospital protocols, telemedicine protocols and a database for case tracking and quarantine tracking. “We have created preventive guidelines, management protocols and treatment recommendations to help in this effort,” said Shugg.

  “In addition, we are looking at patients’ past medical histories, medications as well as location reporting to help monitor the spread of the virus and inform people of their risk, given their medical conditions. TelePlus is fortunate to have experts who have specialized experience in epidemiology and infectious disease.  We have also examined the data from, Wuhan, the city where the virus was first identified, to better manage our population.” 

About The Author

Esther Surden

Esther is the Founder and Editor in Chief of NJ Tech Weekly. This article is republished here with her permission.

Philly EnterpriseTech Highlights March 18 & 19

Philly EnterpriseTech Highlights March 16-17: Amazon ramps hiring; SoftBank cuts WeWork share repurchase plans

Inovio Pharmaceuticals aims to begin clinical trial for coronavirus vaccine next month at Penn

Tom Paine

Plymouth Meeting-based Inovio Pharmaceuticals (NASDAQ: INO ), whose shares have bounced around more than a ping pong ball the past few weeks (see chart), hopes to start clinical trials for its CoronaVirus vaccine candidate in April, the AP reports:

Though the company has virtually no revenue, knowledgeable analysts who follow Inovio are bullish about its capabilities and other drugs in its pipeline. Its market value is slightly less than $1 billion.

It has secured up to $9 million in funding from Coalition for Epidemic Preparedness Innovations, and another $5 million from the Bill and Melinda Gates Foundation to fund development of a smart device for injecting the vaccine.

Meanwhile, a clinical trial for a different vaccine to protect against the new coronavirus will begin tomorrow in Seattle with one patient, the. AP reported.

Philly EnterpriseTech Highlights March 13-15

“The Hunt”, from Universal, finally opens after long delay

Update: “The Hunt” grossed $5.3 million in its opening weekend, 5th among 5 major releases in the worst box office weekend in recent memory. Universal said today that it would make the film and others available online while still playing in theaters.

Tom Paine

The Hunt, a controversal film from Comcast NBC’s Universal, finally opened today after being pulled from distribution before its planned opening last fall. In a situation somewhat similar to The Manchurian Candidate, its screening was delayed in the wake of multiple violent shootings .

The film features an American society where one group of people (elitists) kidnap and. hunt down another group of people. The groups roughly reflect the current divisions cutting through US politics. Its not the type of film Universal usually puts out.

The Hunt is gory, and initial reviews don’t appear too favorable, but we’ll see how it does at the box office. People may not be up to taking it on during the Covid-19 scare.